Urgent

Synthetic cannabinoid toxicity

Novel psychoactive · Toxicology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Toxicity from synthetic cannabinoid receptor agonists ("spice", "K2") which are far more potent than THC, causing agitation, psychosis, seizures, tachycardia, and sometimes AKI and cardiotoxicity.

Red flags

  • Seizures
  • Severe agitation/psychosis
  • Chest pain / arrhythmia
  • AKI / rhabdomyolysis

Assessment

Differential diagnosis

  • Sympathomimetic toxicity
  • Cannabis intoxication
  • Serotonin syndrome
  • Primary psychosis
  • Anticholinergic toxidrome

Investigations

  • Clinical diagnosis (standard cannabis assays do not detect these agents)
  • ECG, U&E (AKI reported), CK, glucose
  • Consider CT/LP if altered mental status unexplained
  • Exclude co-ingestants

Management

  • Provide a calm environment; benzodiazepines for agitation, seizures and tachycardia
  • IV fluids; monitor for rhabdomyolysis and AKI
  • Supportive cardiac monitoring
  • Treat hyperthermia with cooling
  • Observe until agitation and vital signs settle

Drugs & doses

Benzodiazepines (mainstay for agitation/seizures)
IV isotonic fluids
Antiemetics; active cooling if hyperthermic
Antipsychotics with caution for refractory agitation

Disposition

Observe until settled; admit for seizures, AKI or cardiac features; psychiatry if persistent psychosis.

Complications & pitfalls

  • Seizures
  • Acute kidney injury
  • Rhabdomyolysis
  • Cardiac events
  • Prolonged psychosis

Exam pearls

  • Routine cannabinoid immunoassays are usually negative - diagnosis is clinical.
  • Potency and unpredictability far exceed natural cannabis; effects can be severe.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.